Conferences

Advance-HTA research results are continuously communicated at international conferences and events, in order to effectively link decision makers, the broader stakeholder community (including patients and health care professionals) and academia (including other research initiatives on HTA through the EU’s FP7 programme) to the research evidence.

A selection of such dissemination activities is showcased here:

WP1
Asociación de Economía de la Salud (AES) – Pamplona, May 2014
Exploratory analysis of the main variables driving the Drug Reimbursement Decisions in 4 EU countries (presentation).

Health Economists' Study Group – Leeds January 2015

EvaluAES Workshop – Bilbao, April 2015
Exploratory analysis of the main variables driving the Drug Reimbursement and Pricing decisions in 10 EU countries.

HTAi 2015 – Oslo, June 2015

Spanish Health Economics Meeting – Granada, June 2015

IHEA 2015 – Milan, July 2015
Empirical analysis of the main variables driving Drug Reimbursement in 10 European countries: Cancer vs Multiple Sclerosis vs Rheumatoid Arthritis.

Center for Research in Health and Economics (CRES), Universitat Pompeu Fabra – Barcelona, November 2015
What is driving Health Technology Assessment decision-making? Evidence from drug reimbursement decisions.

Joint WP1 and WP2
ISPOR 21st Annual International Meeting – Washington DC, May 2016

XXXVI Spanish Health Economics Meeting – Murcia, June 2016

EUHEA 2016 – Hamburg, July 2016

XXXIV Annual Meeting of the Spanish Epidemiologist Association (SEE) – Sevilla, September 2016
Why are there differences in HTA recommendations across countries? An in-depth case study analysis exploring the interface between the macro and micro-level factors influencing these decisions.

WP2
11th Annual Meeting, Health Technology Assessment International (HTAi) – Washington DC, June 2014
A conceptual and methodological framework for value assessment of medical technologies using MCDA (presentation).

Workshop on Health Technology Assessment, Bulgarian Association for Drug Information (BADI) - Sofia, March 2016
Different approaches to assessing the value of orphan drugs using HTA: Evidence from 4 European countries.

LSE Summit – London, March 2016
Explaining differences in the assessment of value across European countries.

Eurordis Multi-stakeholder Symposium on Improving Patient Access - Brussels, February 2016
Current ways of determining value for rare diseases in Member States

WP3
ISPOR 21st Annual International Meeting – Washington DC, May 2016
Dealing with uncertainty and accounting for social value judgments in value assessments for orphan drugs: Qualitative evidence from four European countries.

XXXVI Spanish Health Economics Meeting – Murcia, June 2016
Assessing the Societal Value in Rare Diseases: A Stated Preference Discrete Choice Experiment in Patients with rare diseases in Italy (poster)

European Health Economic Association (EuHEA) 2016 - Hamburg, July 2016
Assessing the Societal Value in Rare Diseases: A Stated Preference Discrete Choice Experiment in Decision Makers (poster)

WP4
ESHMS 16th biennial congress – Geneva, June 2016
Can patients estimate health related quality of life better than general population: an empirical study (presentation)

EuroQol Meeting – Berlin, 2016
Can patients estimate health related quality of life better than general population: an empirical study (poster)

ISPOR – Vienna, October 2016
Differentiation of health related quality of life outcomes in breast cancer, rheumatoid arthritis, multiple sclerosis, rare cancers and rare diseases: an international survey of patients (poster)

Measuring caregiver quality of life; which aspects really matter? (poster)

Health related quality of life aspects not captured by EQ-5D-5L: results from an international survey of patients (poster)

WP5
11th Annual Meeting, Health Technology Assessment International (HTAi) – Washington DC, June 2014
A taxonomy of medical devices in the logic of HTA.

11th World Congress, International Health Economics Association (iHEA) – Dublin, July 2014
Towards a taxonomy of medical devices in the logic of HTA and economic evaluations rather than marketing authorization.

Eucomed – Brussels, June 2014
Advance HTA – WP5: Mecial Devices (presentation).

HTAi 2015 – Oslo, June 2015
Testing the plausibility of a taxonomy for medical devices in the logic of HTA (poster)

Creating a database on medical devices from an HTA perspective (presentation)

Exploring approaches towards economic evaluation for different types of medical devices based on a taxonomic model in the logic of HTA (presentation)

WP6
HTA and Priority Setting for Universal Health Coverage, PAHO - Washington DC, June 2014
ADVANCE HTA: Advancing and strengthening the methodological tools and practices relating to the application and implementation of Health Technology Assessment (HTA) (presentation)

International Pharmaceutial Payers & HTA Summit, Pharmaccess Leaders Forum – Berlin, October 2014
TBP (presentation).

WP8
Advance-HTA Final dissemination Conference - London, November 2015
Advance-HTA Final dissemination Conference - London, November 2015)

General
HTA 2.0 Europe, European Network for Health Technology Assessment (EUnetHTA) – Rome, October 2014 Advance HTA (poster).

Acronym ADVANCE_HTA
Full title Advancing and strengthening the methodological tools and policies relating to the application and implementation of Health Technology Assessment (HTA)
Project number 305983
CoordinationLSE Health
Consortium 13 partners

The research leading to these results has received funding from the European Community's Seventh Framework Programme FP7/2007-2013 under grant agreement No. 305983.